Historically, AMPs were discovered in competitive ecological niches where their evolution was driven by the need for antimicrobial activity while promoting a long-term ecological sustainability. Clinical AMPs such as Daptomycin, Colistin, and Vancomycin were identified from soil samples , while preclinical compounds like Micrococcin and Lugdunin were isolated from sewage and the human nose, respectively . These peptides often exhibit poor pharmacokinetic (PK) properties, including low solubility and short half-life, traits likely optimized for maintaining long-term ecological balance by selectively targeting competitors without harming mutualistic species [422], as illustrated in Figure .